In this article, we will be looking at the 10 Best Medical Stocks to Buy Under $30.
On April 28, Reuters reported that the US Food and Drug Administration has introduced a new pilot program that would allow the agency to monitor clinical trial data in real time. The agency believes this step could reduce the time it takes to approve new drugs by years and help the US stay competitive with China.
In a call with reporters, FDA Commissioner Marty Makary said the aim of this initiative is to remove “dead time” in the drug development process. He explained that administrative tasks and paperwork make up about 45% of the time needed to move a drug from early testing to submission for an approval decision.
The FDA has published a request for information for input from the public and industry for expanding the pilot program. The agency said that it will accept comments until May 29. It plans to finalize its selection criteria in July and complete pilot selections in August.
Makary also pointed to rising international competition and noted that China overtook the US in the number of Phase 1 clinical trials being conducted around 2021. He added that China’s growth has since been exponential.
With this background in mind, let’s take a look at the 10 best medical stocks to buy under $30.
Our Methodology
To compile our list of the 10 best medical stocks to buy under $30, we used the Finviz stock screener to look for medical stocks with a share price of under $30 as of April 27, 2026. We sorted our results based on market capitalization and picked the top medical stocks. Next, we focused on the top 10 stocks most favored by institutional investors. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey’s Q4 2025 database of 1041 elite hedge funds. Finally, the 10 best medical stocks to buy under $30 were ranked in ascending order based on the number of hedge funds holding stakes in them as of Q4 2025.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Medical Stocks to Buy Under $30
10. Enovis Corporation (NYSE:ENOV)
Enovis Corporation (NYSE:ENOV) is one of the best medical stocks to buy under $30. On April 17, William Blair initiated coverage on Enovis Corporation (NYSE:ENOV), giving the stock an Outperform rating. The research firm pointed to valuation opportunities after the stock has dropped over the past two years.
William Blair said that Enovis Corporation (NYSE:ENOV) is trading at a price-to-earnings ratio of 9 times trailing earnings per share, including stock-based compensation. This is lower than the average of around 15.5 times for peers.
The research firm said that improving free cash flow will be the most important variable for Enovis Corporation’s (NYSE:ENOV) valuation to rise. Management guided free cash flow conversion to reach about 25% in 2026, compared to 10% in 2025. William Blair believes this target is achievable because of reduced cash charges from last year.
Additionally, William Blair supported management’s more conservative growth outlook for 2026, which is projected at 4% to 6%. This is lower than the guidance of more than 6% that the company gave heading into 2024 and 2025. The research firm believes that Enovis Corporation’s (NYSE:ENOV) valuation shows that investors are still skeptical about the company’s performance.
Enovis Corporation (NYSE:ENOV) is a medical technology company focused on developing clinically differentiated solutions in orthopedics and beyond.
9. Azenta, Inc. (NASDAQ:AZTA)
Azenta, Inc. (NASDAQ:AZTA) is one of the best medical stocks to buy under $30. On April 6, Evercore ISI reduced its price target on Azenta, Inc. (NASDAQ:AZTA) from $45 to $35 while maintaining its Outperform rating on the stock. This update came as part of the firm’s first-quarter preview for the medical technology and life science tools sector.
In other news, Azenta, Inc. (NASDAQ:AZTA) announced that Trey Martin has been appointed President of its Multiomics business, effective April 6, 2026. In this new role, Martin will lead the Multiomics division and report directly to the company’s President and Chief Executive Officer, John Marotta.
According to the report by Azenta, Inc. (NASDAQ:AZTA), this appointment is aimed at speeding up progress on its long-range Multiomics plan, which was outlined at the company’s Investor Day in December 2025. The plan focuses on expanding global synthesis capabilities, improving operations, strengthening commercial execution, and driving profitable growth across its integrated Multiomics platform to support performance and wider market adoption.
Meanwhile, Ginger Zhou will step down as President of the Multiomics business but will stay with the company in an advisory capacity through November 2026 to help ensure a smooth transition as the business moves into its next phase of execution.
Azenta, Inc. (NASDAQ:AZTA) is a life sciences company that offers a wide range of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry’s top pharmaceutical, biotech, academic and healthcare institutions around the world.
8. Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is one of the best medical stocks to buy under $30. On April 20, TD Cowen lifted its price target on Tandem Diabetes Care, Inc. (NASDAQ:TNDM) from $25 to $28 and kept its Buy rating on the stock.
The firm updated its financial model after Tandem Diabetes Care, Inc. (NASDAQ:TNDM) announced a pay-as-you-go program in the fourth quarter of 2025. TD Cowen noted that this move to a prescription-based distribution model and the Mobi Tubeless product could help the company achieve a mid-to-high-teens compound annual revenue growth rate.
TD Cowen expects the company to face revenue headwinds of about $85 million to $95 million globally in 2026 as it changes its distribution model. This transition is expected to take Tandem Diabetes Care, Inc. (NASDAQ:TNDM) two to three years as it works toward balancing prescription sales with durable medical equipment channels.
The research firm believes the company will be able to reach gross margins above 65% and EBITDA margins of around 25% when it scales. TD Cowen also noted that higher monthly prescription revenue per patient should offer growth tailwinds in the future.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is a medical device company that specializes in insulin delivery and diabetes technology. It manufactures and sells advanced automated insulin delivery systems.
7. Envista Holdings Corporation (NYSE:NVST)
Envista Holdings Corporation (NYSE:NVST) is one of the best medical stocks to buy under $30. On April 24, Morgan Stanley raised its price target on Envista Holdings Corporation (NYSE:NVST) from $19 to $21 while maintaining an Equal Weight rating on the stock.
The research firm noted that its US dental survey indicates weaker practice volumes during the first quarter. However, Morgan Stanley told investors that demand in the Specialty segment, which includes clear aligners and implants, improved slightly.
Earlier, on April 15, Citi analyst Daniel Grosslight initiated coverage of Envista Holdings Corporation (NYSE:NVST), giving the stock a Neutral rating and setting the price target at $29.
The research firm began coverage of the animal health and dental sector with a “cautiously optimistic” view. Citi prefers the animal health group sector, noting that the pet “humanization” trend should drive increased spending. The research firm pointed out that the dental sector is facing pressure because of a weak economic environment. Citi expects customers to shift toward lower-cost implants and orthodontic products and services.
Envista Holdings Corporation (NYSE:NVST) is a global dental products company that holds a portfolio of more than 30 brands. The company focuses on dental implants and treatment options, orthodontics, and digital imaging technologies.
6. DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is one of the best medical stocks to buy under $30. On April 8, Evercore ISI analyst Elizabeth Anderson cut the firm’s price target on DENTSPLY SIRONA Inc. (NASDAQ:XRAY) from $15 to $13 while maintaining an In Line rating on the stock.
This adjustment comes as part of the firm’s healthcare technology and distribution preview for the first quarter, along with several other adjustments to price targets and additions to Evercore’s Tactical call lists.
In other news, Ariel Investments, an investment management company, stated the following regarding DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in its “Ariel Fund” fourth-quarter 2025 investor letter:
“Also during the quarter, we added Dentsply Sirona (NASDAQ:XRAY), a leading global dental manufacturing company, to the portfolio. Since acquiring Sirona Dental in 2016, the company has faced challenges, particularly in its core capital equipment business, which has come under pressure from lower-cost technology alternatives. Despite these headwinds, we view the dental market favorably given its attractive dynamics: steady growth, lower reimbursement risk, and higher out-of-pocket spending compared to other healthcare segments. Management is executing a strategic reset focused on innovative product development and portfolio expansion, operational efficiencies, emerging market growth and bolt-on acquisitions to strengthen competitive positioning. With these initiatives underway, we believe XRAY is well-positioned to capitalize on secular growth trends, improve margins and drive long-term shareholder value.”
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is the world’s largest manufacturer of professional dental products and technologies. It develops, manufactures, and markets comprehensive solutions, including dental and oral health products as well as other consumable medical devices.
While we acknowledge the potential of XRAY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XRAY and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Medical Stocks to Buy Under $30.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center